The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A pooled analysis of the efficacy and safety of cabozantinib post immunotherapy in patients with advanced renal cell carcinoma.
 
Mototsugu Oya
Honoraria - Bayer; Bristol-Myers Squibb; Novartis; Ono Pharmaceutical; Pfizer
Consulting or Advisory Role - Bayer
Research Funding - Novartis; Pfizer
 
Satoshi Tamada
No Relationships to Disclose
 
Katsunori Tatsugami
No Relationships to Disclose
 
Noboru Nakaigawa
Research Funding - Bayer Yakuhin
 
Takahiro Osawa
No Relationships to Disclose
 
Hiro-Omi Kanayama
Consulting or Advisory Role - Takeda
Speakers' Bureau - Astellas Pharma; Bayer Yakuhin; Janssen; MSD K.K; Ono Pharmaceutical; Pfizer; Takeda
Research Funding - Astellas Pharma; MSD K.K; Nihon Medi-Physics; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Taiho Pharmaceutical; Takeda
 
Chihiro Kondoh
No Relationships to Disclose
 
Naoto Sassa
No Relationships to Disclose
 
Kazuo Nishimura
Honoraria - Astellas Pharma; Novartis
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Janssen
Research Funding - Bayer
 
Masahiro Nozawa
No Relationships to Disclose
 
Naoya Masumori
Speakers' Bureau - Bayer
Research Funding - Bayer; Ono Pharmaceutical; Takeda
 
Yasuhide Miyoshi
No Relationships to Disclose
 
Akiko Kimura
Employment - Takeda
 
Shingo Kuroda
Employment - Takeda
 
Robert J. Motzer
Consulting or Advisory Role - Eisai; Exelixis; Genentech/Roche; Incyte; Lilly; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech/Roche (Inst); Novartis (Inst); Pfizer (Inst)
 
Toni K. Choueiri
Employment - Dana Farber Cancer Hospital
Leadership - ASCO; Dana Farber Cancer Hospital; Kidney Cancer Association; KidneyCan; NCCN
Stock and Other Ownership Interests - Pionyr; Tempest Therapeutics
Honoraria - Alexion Pharmaceuticals; alligent; Analysis Group; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; Exelixis; Foundation Medicine; Genentech/Roche; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Consulting or Advisory Role - Alexion Pharmaceuticals; alligent; Analysis Group; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Research Funding - Agensys (Inst); Analysis Group (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); Cerulean Pharma (Inst); Congressionally Directed Medical Research Programs (DOD) (Inst); Corvus Pharmaceuticals (Inst); Eisai (Inst); Exelixis (Inst); Foundation Medicine (Inst); Gateway for Cancer Research (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Merck (Inst); NCI (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Prometheus (Inst); Roche (Inst); Roche/Genentech (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - -International Patent Application No. PCT/US2018/058430, entitled “Biomarkers of Clinical Response and Benefit to Immune Checkpoint Inhibitor Therapy; International Patent Application No. PCT/US2018/12209, entitled “PBRM1 Biomarkers Predictive of Anti-Immune Checkpoint Response
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; alligent; Analysis Group; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Other Relationship - Medical writing and editorial assistance support may have been funded by Communications companies funded by pharmaceutical companies such as ClinicalThinking, Health Interactions, Envision Pharma Group, Fishawack Group of Companies, Parexel
 
Yoshihiko Tomita
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Novartis; Ono Pharmaceutical; Pfizer
Consulting or Advisory Role - Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Astellas Pharma; AstraZeneca; Chugai Pharma; Ono Pharmaceutical; Pfizer